

ERS Virtual Research Seminar

***Unravelling Severe Exacerbations of COPD.
Collaboration in COPD Exacerbations (CICERO);
an ERS Clinical Research Collaboration***

25 June 2021, Online

09:00 – 09:10 Welcome and introduction - Neil Greening (UK) and Kristina Vermeersch (BE)

Session 1 Characterisation and features of severe exacerbations of COPD

Chairs: Chin Kook Rhee (KR) and Huib Kerstjens (NL)

09:10 – 09:25 *How can treatable traits be used in severe exacerbations?* – Mona Bafadhel, UK

09:25 – 09:40 *Are severe and moderate exacerbations different entities?* – Timm Greulich, DE

09:40 – 09:55 *How can real-world data be used to improve outcomes?* – Jennifer Quint, UK

09:55 – 10:15 Discussion

10:15 – 10:25 *Break*

Session 2 Addressing the non-pulmonary features of hospitalization for exacerbations of COPD

Chairs: Chin Kook Rhee (KR) and Huib Kerstjens (NL)

10:25 – 10:40 *Cardiac dysfunction* – Marco Contoli, IT

10:40 – 10:55 *Sarcopenia and muscle dysfunction* – Neil Greening, UK

10:55 – 11:10 *Palliation and end-of-life care* – Daisy Janssen, NL

11:10 – 11:30 Discussion

11:30 – 11:40 *Break*

Session 3 Treatments at preventing readmission to hospital for COPD

Chairs: Therese Lapperre (BE) and Nicola Scichilone (IT)

11:40 – 11:55 *Pharmacological treatments* – Wim Janssens, BE

11:55 – 12:10 *Ventilation strategies during and after discharge from hospital* – Lara Pisani, IT

12:10 – 12:25 *Rehabilitation strategies around the time of hospitalisation* – Sally Singh, UK

12:25 – 12:45 Discussion

12:45 – 13:30 *Lunch break*

All timings are in Central European Time (CET)

Session 4 Breakout session

13:30 – 15:00 **Group 1:** Phenotyping exacerbations for inflammation, the microbiome, and response.
What are the key targets?
Chair: Mona Bafadhel

Questions that will be answered:

1. *What are the known inflammatory phenotypes of COPD?*
2. *What is known about the eosinophilic, neutrophilic phenotype? Causes, presentation*
3. *Are OCS suitable for everyone?*
4. *Are antibiotics suitable for everyone?*
5. *What other treatments are available? What is missing?*
6. *What techniques are best for characterising the microbiome?*
7. *What does OCS do to the airway microbiome?*

Group 2: What are the key interventions and outcome measure for severe exacerbations of COPD?

Chair: Wim Janssens

Questions that will be answered:

1. *Which outcomes are the most relevant of acute hospitalized exacerbations?*
2. *Do we need more sensitive prognostic scores during and after hospital admission?*
3. *How long do we consider outcomes being determined by the index event?*
4. *What type of interventions need priority for studying in the acute situation?*
5. *Do we need home based monitoring post discharge?*

15:00 – 15:40 Round table discussion of breakout sessions (20min per group)
Chairs: Mona Bafadhel (UK) and Wim Janssens (BE)

15:40 – 15:55 *Break*

Session 5 New horizons for severe exacerbations of COPD

Chairs: Therese Lapperre (BE) and Nicola Scichilone (IT)

15:55 – 16:10 *What new biomarkers are on the horizon for severe exacerbations?* – Pierre-Régis Burgel, FR

16:10 – 16:25 *What data should be collected during severe exacerbations?* – Frits Franssen, NL

16:25 – 16:45 Discussion

16:45 – 16:55 *Break*

Session 6 Next steps for Severe Exacerbations of COPD and CICERO

Chairs: Neil Greening (UK) and Kristina Vermeersch (BE)

16:55 – 17:40 *Facilitated discussion on outcomes of seminar and overview of CATALINA study* – Neil Greening and Kristina Vermeersch

17:40 – 18:00 *Remarks, wrap-up and action points* – Mona Bafadhel and Wim Janssens

All timings are in Central European Time (CET)